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Introduction
In order to provide a point of reference for
a rational approach to the therapy of acute uricemic nephropathy, the metabolic pathways
leading to the production of uric acid will be
I
briefly reviewed .
Uric acid is the end-product of adenine
and guanine metabolism. Relevant to this discussion is the xanthine oxidase enzyme which
catalyzes the conversion of hypoxanthine to
xanthine and xanthine to uric acid. In children
with acute leukemia the increasing production
and subsequent destruction of white blood cells
result in the rapid elevation of uric acid concentration in the plasma, especially during treatment with antineoplastic drugs. This in turn may
lead to the development of acute hyperuricemic
nephropathy. 1 - 4
The uric acid deposition in the renal medulla causes obstructive uropathies. This occurrence is not uncommon in children treated for
reticuloendothelial malignancies, sarcoma and
acute lymphocytic leukemia.
Incidence
The work done at the National Cancer Institute of the National Institutes of Health (NIH)
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showed that 6 out of 5 7 patients with acute leukemia developed uric acid nephropathy. 4 The
treatment had consisted of methotrexate, 6mercaptopurine, hydrocortisone and cortisone.
The duration of treatment before the clinical onset of hyperuricemic nephropathy was from
three to six days. The maximum elevation of
white cells was 11,800 to 18,000 per mm 3 ; of
uric acid from 1 7 to 71 ; and of BUN from 51 to
212 mg/1 OOml.
A number of subsequent reports have amply confirmed and extended these observations
of Frei et al,4 and a number of conclusions can
be made.

Risk Factors
Uric acid nephropathy is more prone to
develop in the treatment of acute lymphocytic
leukemia when the following conditions are
present: elevation of white blood cells to more
than 20,000 / mm 3 , marked adenopathy, especially in the mediastinum, and massive hepatosplenomegaly.
The histology of severe uric acid nephropathy includes intratubular hydronephrosis and
infarction from uric acid obstruction 5 · 6 ; the
milder and more common form of uric acid nephropathy shows marked renal enlargement
produced by the intense interstitial leukemic infiltration; the glomeruli and tubules are intact.
There is a good correlation between the kidney

and liver size in patients with less than 5% leukemic infiltration of these organs. 4

leLJcocytosis, leucopenia and, rarely, peripheral
neuritis and bone marrow depression .

Treatment
The first two modes of treatment rely on
the provisions of a more favorable situation for
the deposition of uric acid which is reduced
when the urinary pH is made alkaline in excess
of 6, beyond which point the solubility of uric
acid is increased in an exponential fashion .
To insure a good urine output , intravenous
5% dextrose/water is administered at a rate of
3000 ml/m 2 /day. To promote uric acid solubility and therefore enhance excretion, the urine
may be made alkaline by administering intravenous sodium bicarbonate at a dosage calculated to elevate the serum bicarbonate by 1 0
mEq/liter, and/or the use of a carbonic anhydrase inhibitor acetazolamide to block the renal
tubular reabsorption of bicarbonate. The aims
of these general measures are to achieve a urinary pH in excess of 6 and a urine volume in excess of 60 ml/m 2 /hour.
If the urine output is less than 60 ml/m 2 /
hour after rehydration, mannitol (25% aqueous
solution) is given initially over a 5- to 1 0-minute
period in a test dose of 6 .25 gm in children
weighing less than 30 kg and 12 .5 gm in children weighing over 30 kg . If diuresis ensues,
additional mannitol is administered in the same
dose every 6 hours to achieve a urine output of
at least 60 ml/m 2 /hour.
It is important to obtain and record urine
volume, pH, body weight, vital signs, blood uric
acid, electrolytes , BUN, and calcium concentrations every 1 2 to 24 hours.
Normal glomerular filtration rates are
achieved within 2 to 1 4 days of treatment of hyperuricemia with fluids , bicarbonate and acetazolamide. 7

Special Therapy
The rapid removal of uric acid can be
achieved by either peritoneal dialysis or hemodialysis.
Peritoneal dialysis removes uric acid at a
rate of 1 5 ml/min, but hemodialysis is at least
five times more effective . 1 · 2 The decision on
when to institute these procedures is a clinical
one and is based on the physician 's past experience and the patient's status . One example of
this complex clinical decision is shown in the
Figure .

Allopurinol
Allopurinol (1 0 mg/kg/day initial oral
dose) is a useful drug for the treatment of hyperuricemia. 7 · 8 Allopurinol is a potent inhibitor of
xanthine oxidase for which it is also a substrate .
Although the incidence of side effects is
very low, the potential complications of allopurinol treatment should always be kept in mind .
These include skin and blood dyscrasias, malaise, fever, complaints of nausea, headache,
vomiting, vertigo, drowsiness and gastric irritation, muscle ache, elevation of SGOT /SGPT,
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Figure--Acute uric acid nephropathy and treatment with
hemodialysis is illustrated in the clinical course of a 1 4-yearold white boy.
Acute uric acid nephropathy occurred at the time
of leukemic relapse. Diuresis did not occur despite
all the general treatment procedures. Peritoneal
dialysis was only partially successful in the removal of 4 gm of uric acid in 24 hours without
lowering the serum uric acid concentration. Hemo
dialysis was instituted and removed over 1 7 gm of
uric acid resulting in a decrease of serum uric acid
from 87 to 29 mg/di. Immediately following dialysis, he was given 25 gm of intravenous mannitol
and was started on allopurinol. However, anuria
persisted and a second course of hemodialysis
was performed for 6 hours, resulting in a decrease
of serum uric acid from 46 to 19 mg/di. Just before the completion of the dialysis, he voided 340
ml of urine and the output remained adequate
thereafter aided by good fluid and conservative
medical management.
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The use of hemodialysis is dependent on
machine availability and the existence of a specially trained nephrology team consisting of
dialysis technicians, nurses, surgeons, and
nephrologists. Peritoneal dialysis requires less
technical hardware and can be initiated more
promptly by the nephrologist; whereas, before
hemodialysis can be initiated, vascular access
and somewhat extensive preparations are
needed, especially in small children in the 2- to
3-year age group, where uric acid nephropathy
more commonly occurs.
There is a relationship between the days
of oliguria before dialysis has been started and
the number of days until diuresis begins 2 which
has been taken as an indication for the early institution of either of these special procedures
within a day or two of anuria and/or rapidly rising serum uric acid concentrations.

Summary
Hyperuricemic acute nephropathy occurs
in 1 0% of patients with leukemia; the intrarenal
uric acid deposition results in obstructive uropathy.
The clinical findings which point to the
likelihood of renal damage are: first, an initial
white blood cell count in excess of 20,000/
mm 3 ; second, marked adenopathy especially in
the mediastinum; and third, the presence of
massive hepatosplenomegaly. The aim of general treatment with fluids and renal alkalinization
is to promote uric acid solubility and output by
maintaining urine pH in excess of 6 and urine
volume in excess of 60 ml/m 2 / hr. The discovery and clinical use of allopurinol, an analogue
of hypoxanthine and an inhibitor as well as a
substrate of the enzyme xanthine oxidase, is
central to the control of hyperuricemia. Allopurinol , as well as its metabolic end-product, alloxanthine, acts at the terminal steps of uric acid
metabolism to reduce the production of uric
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acid and in conjunction with the other general
medical therapy, contributes to the reversal of
the hyperuricemia.
Finally, the special extrarenal procedures
of peritoneal dialysis and hemodialysis can rapidly, efficiently and safely remove the uric acid
from the body. The sooner one initiates either of
these procedures, the earlier diuresis begins.
Acknowledgment: The author thanks Mrs.
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The Figure is reproduced with permission from Journal of Pediatrics(7 2:358 -366, 1968)
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